TLDR:
Key Points:
- Sense4Med, a startup in Rome, Italy, raised €510k in funding for developing point-of-care devices for cystic fibrosis diagnosis.
- Backers included Innova Venture and Scientifica Venture Capital.
Sense4Med, a Rome-based startup, has secured €510k in funding from investors including Innova Venture and Scientifica Venture Capital. The company, a spin-off of the University of Tor Vergata, is focused on developing innovative point-of-care devices for the diagnosis of cystic fibrosis, a serious genetic disease affecting the respiratory and digestive systems.
Led by CEO Fabiana Arduini, a full professor of Analytical Chemistry, Sense4Med aims to simplify the diagnostic process of cystic fibrosis using paper-based electrochemical biosensors. The technology promises non-invasive and rapid detection of the disease through a sweat test, which can be used across all age groups and physical conditions. The funding will be used to expand operations and further develop the device for commercialization.
Arduini expressed excitement about the funding round, highlighting the potential of their technology to transform the diagnosis and management of cystic fibrosis. The startup’s team, which includes experts in various fields, is dedicated to advancing the innovative device to make a significant impact on healthcare.
